Share This Article:

Role of Hormone Replacement Therapy in Young Women Suffering from Menopausal Symptoms of Cancer —A Concise Review

DOI: 10.4236/oalib.1102069    663 Downloads   1,285 Views  

ABSTRACT

Abstract: Cancer survivors are faced with several survivorship issues. In addition, young women may have to face the challenges brought on by premature menopause. The issue of Hormone Replacement Therapy (HRT) in these young ladies has always been a matter of debate. This article reviews the current recommendations for the use of HRT in various cancers. The newer hormonal replacement therapies have also been discussed.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Lokanatha, D. , Babu, K. and Bhat, G. (2015) Role of Hormone Replacement Therapy in Young Women Suffering from Menopausal Symptoms of Cancer —A Concise Review. Open Access Library Journal, 2, 1-8. doi: 10.4236/oalib.1102069.

References

[1] King, J., Wynne, C.H., Assersohn, L. and Jones, A. (2011) Hormone Replacement Therapy and Women with Premature Menopause—A Cancer Survivorship Issue. European Journal of Cancer, 47, 1623-1632.
http://dx.doi.org/10.1016/j.ejca.2011.04.007
[2] Schover, L.R. (2008) Premature Ovarian Failure and Its Consequences: Vasomotor Symptoms, Sexuality, and Fertility. Journal of Clinical Oncology, 26, 753-758.
http://dx.doi.org/10.1200/JCO.2007.14.1655
[3] Cusack, L., Brennan, M., Baber, R. and Boyle, F. (2013) Menopausal Symptoms in Breast Cancer: Management Update. British Journal of General Practice, 63, 51-52.
http://dx.doi.org/10.3399/bjgp13X660977
[4] Finck, G., Barton, D.L., Loprinzi, C.L., et al. (1998) Definitions of Hot Flashes in Breast Cancer Survivors. Journal of Pain and Symptom Management, 16, 327-333.
http://dx.doi.org/10.1016/S0885-3924(98)00090-6
[5] Kronenberg, F. (1994) Hot Flashes: Phenomenology, Quality of Life, and Search for Treatment Options. Experimental Gerontology, 29, 319-336.
http://dx.doi.org/10.1016/0531-5565(94)90012-4
[6] Ganz, P.A., Greendale, G.A., Petersen, L., et al. (2003) Breast Cancer in Younger Women: Reproductive and Late Health Effects of Treatment. Journal of Clinical Oncology, 21, 4184-4193.
http://dx.doi.org/10.1200/JCO.2003.04.196
[7] Hickey, M., Saunders, C.M. and Stuckey, B.G.A. (2005) Management of Menopausal Symptoms in Patients with Breast Cancer: An Evidence-Based Approach. The Lancet Oncology, 6, 687-695.
http://dx.doi.org/10.1016/S1470-2045(05)70316-8
[8] Perrone, A.M., Pozzati, F., Santini, D., Rossi, M., Procaccini, M., Casalini, L., et al. (2014) Gynecological Malignancies and Hormonal Therapies: Clinical Management and Recommendations. World Journal of Obstetrics and Gynecology, 3, 162-170.
[9] Casper, R.F. (1996) Regulation of Estrogen/Progestogen Receptors in the Endometrium. International Journal of Fertility and Menopausal Studies, 41, 16-21.
[10] NCCN Guidelines Version 2. 2013 Invasive Breast Cancer, Definition of Menopause.
http://www.nccn.org/
[11] Murthy, V. and Chamberlain, R.S. (2012) Menopausal Symptoms in Young Survivors of Breast Cancer—A Growing Problem without an Ideal Solution. Cancer Control, 19, 317-329.
[12] Minton, S.E. and Munster, P.N. (2002) Chemotherapy-Induced Amenorrhea and Fertility in Women Undergoing Adjuvant Treatment for Breast Cancer. Cancer Control, 9, 466-472.
[13] Anderson, R.A., Themmen, A.P., Al-Qahtani, A., Groome, N.P. and Cameron, D.A. (2006) The Effects of Chemotherapy and Long-Term Gonadotrophin Suppression on the Ovarian Reserve in Premenopausal Women with Breast Cancer. Health Human Reproduction, 21, 2583-2592.
http://dx.doi.org/10.1093/humrep/del201
[14] Tominaga, T., Morimoto, T. and Ohasi, Y., for the Japan Letrozole Study Group (2000) A Pivotal Double-Blind Trial in Japan of an Aromatase Inhibitor Letrozole (Third Generation) vs. Its Predecessor Fadrozole Hydrochloride (Second Generation). Annals of Oncology, 11, 25.
[15] Tham, Y.L., Sexton, K., Weiss, H., Elledge, R., Friedman, L.C. and Kramer, R. (2007) The Rates of Chemotherapy-Induced Amenorrhea in Patients Treated with Adjuvant Doxorubicin and Cyclophosphamide Followed by Ataxane. American Journal of Clinical Oncology, 30, 126-132.
http://dx.doi.org/10.1097/01.coc.0000251398.57630.4f
[16] Lutchman, S.K., Muttukrishna, S., Stein, R.C., McGarrigle, H.H., Patel, A., Parikh, B., et al. (2007) Predictors of Ovarian Reserve in Young Women with Breast Cancer. British Journal of Cancer, 96, 1808-1816.
http://dx.doi.org/10.1038/sj.bjc.6603814
[17] Oktay, K., Oktem, O., Reh, A. and Vahdat, L. (2006) Measuring the Impact of Chemotherapy on Fertility in Women with Breast Cancer. Journal of Clinical Oncology, 24, 4044-4046.
http://dx.doi.org/10.1200/JCO.2006.06.9823
[18] Thygesen, K.H., Schjø;dt, I. and Jarden, M. (2012) The Impact of Hematopoietic Stem Cell Transplantation on Sexuality: A Systematic Review of the Literature. Bone Marrow Transplantation, 47, 716-724.
http://dx.doi.org/10.1038/bmt.2011.169
[19] Meirow, D. (2000) Reproduction Post-Chemotherapy in Young Cancer Patients. Molecular and Cellular Endocrinology, 169, 123-131.
http://dx.doi.org/10.1016/S0303-7207(00)00365-8
[20] Blumenfeld, Z. (2002) Preservation of Fertility and Ovarian Function and Minimalization of Chemotherapy Associated Gonadotoxicity and Premature Ovarian Failure: The Role of Inhibin-A and -B as Markers. Molecular and Cellular Endocrinology, 187, 93-105.
http://dx.doi.org/10.1016/S0303-7207(01)00712-2
[21] Pagani, O. and Goldhirsch, A. (2006) Breast Cancer in Young Women: Climbing for Progress in Care and Knowledge. Women’s Health, 2, 717-732.
http://dx.doi.org/10.2217/17455057.2.5.717
[22] Holmberg, L. and Anderson, H. (2004) HABITS Steering and Data Monitoring Committees. HABITS (Hormonal Replacement Therapy after Breast Cancer—Is It Safe?), a Randomized Comparison: Trial Stopped. Lancet, 363, 453-455.
http://dx.doi.org/10.1016/S0140-6736(04)15493-7
[23] Rossouw, J.E., Anderson, G.L., Prentice, R.L., et al. (2002) Risks and Benefits of Estrogenplus Progestin in Healthy Postmenopausal Women: Principal Results from the Women’s Health Initiative Randomized Controlled Trial. JAMA, 288, 321-333.
http://dx.doi.org/10.1001/jama.288.3.321
[24] Chlebowski, R.T., Schwartz, A.G., Wakelee, H., et al. (2009) Oestrogen plus Progestinand Lung Cancer in Postmenopausal Women (Women’s Health Initiative Trial): Apost-Hoc Analysis of a Randomised Controlled Trial. Lancet, 374, 1243-1251.
http://dx.doi.org/10.1016/S0140-6736(09)61526-9
[25] Kenemans, P., Bundred, N.J., Foidart, J.M., Kubista, E., von Schoultz, B., Sismondi, P., et al. (2009) Safety and Efficacy of Tibolone in Breast-Cancer Patients with Vasomotor Symptoms: A Double-Blind, Randomized, Non-Inferiority Trial. Lancet Oncology, 10, 135-146.
http://dx.doi.org/10.1016/S1470-2045(08)70341-3
[26] Gralow, J.R., Blermann, J.S., Farooki, A., Fornier, M.N., Gagel, R.F., Kumar, R., et al. (2013) NCCN Task Force Report: Bone Health in Cancer Care. Journal of the National Comprehensive Cancer Network: JNCCN, 11, S1-S50.
[27] Barakat, R.R., Bundy, B.N., Spirtos, N.M., Bell, J. and Mannel, R.S. (2006) Randomized Double-Blind Trial of Estrogen Replacement Therapy versus Placebo in Stage I or II Endometrial Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 24, 587-592.
http://dx.doi.org/10.1200/JCO.2005.02.8464
[28] Chu, M.C., Mor, G., Lim, C., Zheng, W., Parkash, V. and Schwartz, P.E. (2003) Low-Grade Endometrial Stromal Sarcoma: Hormonal Aspects. Gynecologic Oncology, 90, 170-176.
http://dx.doi.org/10.1016/S0090-8258(03)00258-0
[29] de Villiers, T.J., Pines, A., Panay, N., Gambacciani, M., Archer, D.F., Baber, R.J., et al., on Behalf of the International Menopause Society (2013) Updated 2013 International Menopause Society Recommendations on Menopausal Hormone Therapy and Preventive Strategies for Midlife Health. Climacteric, 16, 316-337.
http://dx.doi.org/10.3109/13697137.2013.795683
[30] Donders, G., Neven, P., Moegele, M., Lintermans, A., Bellen, G., Prasauskas, V., et al. (2014) Ultra-Low-Dose Estriol and Lactobacillus acidophilus Vaginal Tablets (Gynoflor ®) for Vaginal Atrophy in Postmenopausal Breast Cancer Patients on Aromatase Inhibitors: Pharmacokinetic, Safety, and Efficacy Phase I Clinical Study. Breast Cancer Research and Treatment, 145, 371-379.
http://dx.doi.org/10.1007/s10549-014-2930-x
[31] NCCN Guidelines Version 2. 2015, Survivorship, Discussion, MS-30.
http://www.nccn.org/

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.